Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657835 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL16727015 | 0.85 | KDM4E (0.54) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL30016388 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL19331148 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL22013885 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1LMNATDP1POLB | |
| SCHEMBL16729379 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL2657252 | 0.80 | GCK (0.53) | KDM4EALDH1A1 | |
| SCHEMBL20944369 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL19330210 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL2656280 | 0.78 | KMT2A (0.52) | KDM4EALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4148053-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3426255-B1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-10981891-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10508097-B2 | Antibacterial compounds and uses thereof | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190071417-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-3426255-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | The Global Alliance for TB Drug Development, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155909-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2009083553-A1 | AZINE COMPOUNDS AS GLUCOKINASE ACTIVATORS | RHEOSCIENCE A/S (DK) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009083553-A1 | AZINE COMPOUNDS AS GLUCOKINASE ACTIVATORS | RHEOSCIENCE A/S (DK) | 2009-07-09 | — | — | WO | disclosed |
| US-6420363-B1 | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6291508-B1 | POTENT ABILITY TO BIND TO RETINOIC ACID RECEPTORS THUS USEFUL IN TREATING PSORIASIS AND RHEUMATOID ARTHRITIS. | EISAI CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| US-6133283-A | Mono- or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6030964-A | BINDS TO RETINOIC ACID RECEPTORS AND USEFUL FOR TREATING PSORIASIS, AUTOIMMUNE DISEASES, TUMORS, RHEUMATOID ARTHRITIS AND FOR INDUCING IMMUNOSUPPRESSION IN ORGAN TRANSPLANTATION | EISAI CO., LTD. (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5977125-A | Mono-or polyenic carboxylic acid derivatives | EISAI CO., LTD. (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0790228-A1 | MONO- OR POLYENIC CARBOXYLIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981891-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | KDM4E 3810/4885ALDH1A1 518/4885CA12 3630/4885 |
| US-20200039955-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | KDM4E 3810/4885ALDH1A1 518/4885CA12 3630/4885 |
| US-10508097-B2 | Antibacterial compounds and uses thereof | CFTR, SQOR, NQO1 | KDM4E 3810/4885ALDH1A1 518/4885CA12 3630/4885 |
| US-20190071417-A1 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | CFTR, SQOR, NQO1 | KDM4E 3810/4885ALDH1A1 518/4885CA12 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.